A Real-World Comparison of Pazopanib Versus Sunitinib in Metastatic Renal Cell Carcinoma: Focus on Poor-Risk patients, A Single-Center Study
Received Date : 29 May 2020
Accepted Date : 17 Oct 2020
Available Online : 30 Oct 2020
Doi: 10.37047/jos.2020-76764 - Article's Language: EN
J Oncol Sci. 2020;6(3):153-63
This is an open access article under the CC BY-NC-ND license
Objective: The efficacy of pazopanib and sunitinib are comparable in favorable-to intermediate-risk metastatic renal cell carcinoma (mRCC) patients. However, whether pazopanib or sunitinib have different outcomes in poor-risk patients is unknown. This study aimed to investigate the efficacy of these drugs in a real-world poor-risk patient population. Material and Methods: The medical records of 46 mRCC patients treated with sunitinib or pazopanib between 2012 and 2018 in the outpatient clinic in the Department of Medical Oncology, Faculty of Medicine, Eskisehir Osmangazi University were retrospectively evaluated. Risk classification was done based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) system. Results: The objective response rate (ORR) was significantly higher in patients treated with pazopanib than in those treated with sunitinib (50% vs. 16.7%; p=0.038). The median progression-free survival (PFS) was six months in the sunitinib group and 9.9 months in the pazopanib group, among poor-risk patients only (p=0.36). However, the median PFS was almost equal between the sunitinib and pazopanib group, among favorable- to intermediate-risk patients (12.4 months vs. 13.9 months; p=0.97). Anemia, elevated liver function tests, hand and foot syndrome, and hyponatremia were higher in patients treated with pazopanib. However, neutropenia and leucopenia were more frequent in patients treated with sunitinib. Conclusion: Pazopanib might be an appropriate first-line therapy in poor-risk mRCC due to improved PFS rates and ORRs compared to sunitinib. However, extensive, multi-center, prospective studies are required to support these results.
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. [Crossref]  [PubMed] 
  2. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894-906. [Crossref]  [PubMed] 
  3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843-852. [Crossref]  [PubMed] 
  4. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799. [Crossref]  [PubMed] 
  5. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-148. [Crossref]  [PubMed]  [PMC] 
  6. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6 Suppl 1:S55-S57. [PubMed] 
  7. Fosså SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000;27(2):187-193. [PubMed] 
  8. Bedke J, Gauler T, Grünwald V, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35(2):179-188. [Crossref]  [PubMed]  [PMC] 
  9. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134. [Crossref]  [PubMed] 
  10. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. [Crossref]  [PubMed] 
  11. Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111. [Crossref]  [PubMed] 
  12. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068. [Crossref]  [PubMed] 
  13. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731. [Crossref]  [PubMed] 
  14. Motzer RJ, Tannir NM, McDermott DF, et al; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. [Crossref]  [PubMed]  [PMC] 
  15. George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Oncologist. 2019;24(11):1497-1501. [Crossref]  [PubMed]  [PMC] 
  16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. [Crossref]  [PubMed] 
  17. World Health Organization. WHO handbook for reporting results of cancer treatment. World Health Organization. ‎1979‎. [Link] 
  18. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281. [Crossref]  [PubMed] 
  19. Tannir NM, Msaouel P, Ross JA, et al. Temsirolimus versus Pazopanib (TemPa) in patients with advanced clear-cell renal cell carcinoma and poor-risk features: a randomized phase II trial. Eur Urol Oncol. 2020;3(5):687-694. [Crossref]  [PubMed]  [PMC] 
  20. Lee JL, Park I, Park K, et al. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. J Cancer Res Clin Oncol. 2012;138(4):687-693. [Crossref]  [PubMed] 
  21. Ruiz-Morales JM, Swierkowski M, Wells JC, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer. September 2016;65:102-108. [Crossref]  [PubMed] 
  22. Lalani AA, Li H, Heng DYC, et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Can Urol Assoc J. 2017;11(3-4):112-117. [Crossref]  [PubMed]  [PMC] 
  23. Kim MS, Chung HS, Hwang EC, et al. Efficacy of first-line targeted therapy in real-world korean patients with metastatic renal cell carcinoma: focus on sunitinib and pazopanib. J Korean Med Sci. 2018;33(51):e325. [Crossref]  [PubMed]  [PMC] 
  24. Bjarnason GA, Knox JJ, Kollmannsberger CK, et al. Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC). J Clin Oncol. 2015;33(15_Suppl):4555. [Crossref] 
  25. Bracarda S, Iacovelli R, Boni L, et al; Rainbow Group. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26(10):2107-2113. [Crossref]  [PubMed] 
  26. Kim JH, Park I, Lee JL. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemother Pharmacol. 2016;78(2):325-332. [Crossref]  [PubMed]